

ONE HUNDRED NINETEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON ENERGY AND COMMERCE  
2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-3641  
Minority (202) 225-2927

March 27, 2025

The Honorable Brett Guthrie  
Chairman  
House Committee on Energy and Commerce  
2125 Rayburn House Office Building  
Washington, D.C. 20515

The Honorable H. Morgan Griffith  
Chairman  
Subcommittee on Health  
House Committee on Energy and Commerce  
2125 Rayburn House Office Building  
Washington, D.C. 20515

Dear Chairman Guthrie and Chairman Griffith:

We write today to follow up on Chairman Griffith’s commitment made during the February 11, 2026, Health Subcommittee hearing relating to oversight of the voluntary drug pricing agreements made between pharmaceutical manufacturers and the White House. As you may recall, Chairman Griffith recognized the necessity of better understanding these agreements and noted that he was “happy to work with [you]...in order to get as much information as we can...”<sup>1</sup> As leaders of the Committee on Energy and Commerce, we are responsible for upholding and vigorously exercising Congress’s constitutional mandate for oversight of the executive branch. Unfortunately, the Trump Administration has ignored the request by Democratic committee health leaders earlier this month to hand over these secret deals so Congress and the American people can see what is in them.<sup>2</sup> Since Chair Griffith said he was a “big believer in transparency, and the more we know, the better job we can do as Congressmen,” we are now asking you to join us in demanding that the Administration provide these secret written agreements with pharmaceutical companies to Congress. Only then will we be able to

---

<sup>1</sup> House Committee on Energy and Commerce, *Hearing on Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain*, 119th. Cong. (Feb. 11, 2026).

<sup>2</sup> Letter from Rep. Frank Pallone, Jr., Ranking Member, House Committee on Energy and Commerce, Richard E. Neal, Ranking Member, House Committee on Ways and Means, Robert C. “Bobby” Scott, Ranking Member, House Committee on Education and Workforce, and Ron Wyden, Ranking Member, Senate Committee on Finance, to President Donald J. Trump (Mar. 5, 2026).

The Honorable Brett Guthrie  
The Honorable H. Morgan Griffith  
March 27, 2026  
Page 2

understand the true implications of these agreements on the prices the American people pay for their prescription drugs.

As you know, 16 pharmaceutical manufacturers have individually struck confidential deals with the White House to lower the price of some of their drugs in exchange for a reprieve from tariffs, as well as “future pricing mandates” in certain instances. On July 31, 2025, the White House sent letters to 17 major drugmakers with a list of demands, including that companies lower the price of their products in accordance with most-favored-nation reference pricing. On top of separate threats of steep pharmaceutical tariffs, the letters leveled a vague ultimatum if drugmakers did not accede to the President’s demands by September 29, 2025. To date, 16 companies have acquiesced and entered into agreements with the White House, but exactly what they agreed to and what the President offered them in return has not yet been made public.

It is also unclear from public information the mechanisms by which these deals will meaningfully lower drug prices for Americans or what enforcement tools the deals contemplate to ensure compliance. It is true that, as Chairman Griffith stated in the February 12 Health Subcommittee hearing, “the problem is, all of these agreements have secrecy deals.” In fact, almost every press release issued by the pharmaceutical companies that have entered into these agreements notes that the “terms of this agreement remain confidential.” However, that is untenable given the fact that this agreement was reached with the federal government under the guise of lowering drug prices. This serious lack of transparency prevents lawmakers and the American people from assessing the effectiveness of the approach.

In the February 11 Health Subcommittee hearing, Chairman Griffith expressed a willingness to work with us to get more information about these deals. We thank you for your statement and request that you follow through on your commitment to help us obtain this information so that we can conduct effective oversight of drug costs in our nation.

Sincerely,



Frank Pallone, Jr.  
Ranking Member



Diana DeGette  
Ranking Member  
Subcommittee on Health